famotidine has been researched along with Chronic Primary Open Angle Glaucoma in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwetz, BA | 1 |
1 other study available for famotidine and Chronic Primary Open Angle Glaucoma
| Article | Year |
|---|---|
From the Food and Drug Administration.
Topics: Anti-Ulcer Agents; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus; Drug Labeling; F | 2001 |